Vivos Therapeutics, Inc. (VVOS): Nasdaq/NYSE listing notice — Vivos receives Nasdaq deficiency notice for late Q3 10-Q; expects to file in weeks

Vivos Therapeutics, Inc.

Nasdaq notified Vivos of non-compliance with Listing Rule 5250(c)(1) for late Q3 2022 Form 10-Q.
This is the second delinquency; Q2 2022 filing was also late and previously disclosed.
Company expects to submit a compliance plan to Nasdaq allowing until February 20, 2023 to regain compliance.
Revenue recognition issues (ASC 606) have been resolved; Q1 2022 10-Q restated on November 25, 2022.
Vivos plans to file both Q2 and Q3 2022 10-Qs in the coming weeks, which would cure the deficiency.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

November 16, 2022, Vivos Therapeutics, Inc. (the “Company”) received a staff deficiency notice from The Nasdaq Stock Market (“Nasdaq”) indicating that, because Nasdaq has not yet received the Company’s Form 10-Q for the quarter ended September 30, 2022, the Company no longer complies with the Nasdaq Listing Rules for continued listing under Rule 5250(c)(1) (the “Periodic Filing Requirement”). Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. As reported in a press release dated August 26, 2022, the Company previously received a d

View on SEC.gov

Browse all listing & compliance notices →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-033887

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.